Aclarion Announces First Commercial Agreement in Michigan
Aclarion, Inc. (Nasdaq: ACON) has announced its first commercial agreement in Michigan with Sheridan Community Hospital. This agreement brings Nociscan, Aclarion's innovative solution for identifying chronic low back pain, to central Michigan and to Dr. John Keller, a leading neurosurgeon and Aclarion medical advisor.
Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain, providing critical insights when used with other diagnostic tools.
This agreement is part of Aclarion's strategy to expand access to Nociscan in the US market, following recent insurance coverage announcements in the UK. It represents a step towards potential payer coverage in the United States.
Aclarion, Inc. (Nasdaq: ACON) ha annunciato il suo primo accordo commerciale nel Michigan con l'Ospedale Comunitario di Sheridan. Questo accordo porta Nociscan, la soluzione innovativa di Aclarion per identificare il dolore cronico alla schiena, nella parte centrale del Michigan e al Dr. John Keller, un neurologo di spicco e consigliere medico di Aclarion.
Nociscan è la prima piattaforma SaaS supportata da evidenze in grado di aiutare i medici a distinguere tra dischi dolorosi e non dolorosi nella colonna lombare in modo non invasivo. Quantifica obiettivamente i biomarcatori chimici associati al dolore ai dischi, fornendo informazioni critiche quando utilizzata con altri strumenti diagnostici.
Questo accordo fa parte della strategia di Aclarion per ampliare l'accesso a Nociscan nel mercato statunitense, dopo recenti annunci di copertura assicurativa nel Regno Unito. Rappresenta un passo verso una potenziale copertura per i pagatori negli Stati Uniti.
Aclarion, Inc. (Nasdaq: ACON) ha anunciado su primer acuerdo comercial en Michigan con el Hospital Comunitario de Sheridan. Este acuerdo lleva Nociscan, la solución innovadora de Aclarion para identificar el dolor crónico de espalda, al centro de Michigan y al Dr. John Keller, un neurocirujano destacado y asesor médico de Aclarion.
Nociscan es la primera plataforma SaaS respaldada por evidencia que ayuda a los médicos a distinguir entre discos dolorosos y no dolorosos en la columna lumbar de manera no invasiva. Cuantifica objetivamente los biomarcadores químicos asociados con el dolor discal, proporcionando información crítica cuando se utiliza con otras herramientas diagnósticas.
Este acuerdo es parte de la estrategia de Aclarion para ampliar el acceso a Nociscan en el mercado estadounidense, tras recientes anuncios de cobertura de seguros en el Reino Unido. Representa un paso hacia una posible cobertura de los pagadores en los Estados Unidos.
Aclarion, Inc. (Nasdaq: ACON)는 셔리던 커뮤니티 병원과의 미시간에서의 첫 상업 계약을 발표했습니다. 이 계약은 Aclarion의 혁신적인 솔루션인 Nociscan을 미시간 중부와 존 켈러 박사에게 제공합니다. 그는 저명한 신경외과 의사이자 Aclarion의 의료 자문위원입니다.
Nociscan은 증거 기반의 첫 번째 SaaS 플랫폼으로, 비침습적으로 의사들이 요추의 통증 있는 디스크와 비통증 있는 디스크를 구별하는 데 도움을 줍니다. 디스크 통증과 관련된 화학 생체 표지자를 객관적으로 정량화하여, 다른 진단 도구와 함께 사용할 때 중요한 통찰력을 제공합니다.
이 계약은 최근 영국에서의 보험 보장 발표에 이어 Aclarion의 Nociscan에 대한 접근 확대 전략의 일환입니다. 이는 미국 내 잠재적 지불자 보장을 위한 한 걸음이 됩니다.
Aclarion, Inc. (Nasdaq: ACON) a annoncé son premier accord commercial dans le Michigan avec l'Hôpital Communautaire de Sheridan. Cet accord apporte Nociscan, la solution innovante d'Aclarion pour identifier la douleur chronique au dos, dans le centre du Michigan et au Dr. John Keller, un neurochirurgien de premier plan et conseiller médical d'Aclarion.
Nociscan est la première plateforme SaaS soutenue par des preuves qui aide les médecins à distinguer entre les disques douloureux et non douloureux dans la colonne lombaire de manière non invasive. Elle quantifie objectivement les biomarqueurs chimiques associés à la douleur discale, fournissant des informations cruciales lorsqu'elle est utilisée avec d'autres outils diagnostiques.
Cet accord fait partie de la stratégie d'Aclarion pour élargir l'accès à Nociscan sur le marché américain, après des annonces récentes concernant la couverture d'assurance au Royaume-Uni. Cela représente un pas vers une couverture potentielle des payeurs aux États-Unis.
Aclarion, Inc. (Nasdaq: ACON) hat sein erstes Handelsabkommen in Michigan mit dem Sheridan Community Hospital bekannt gegeben. Dieses Abkommen bringt Nociscan, Aclarions innovative Lösung zur Identifizierung von chronischen Rückenschmerzen, ins zentrale Michigan und zu Dr. John Keller, einem führenden Neurochirurgen und medizinischen Berater von Aclarion.
Nociscan ist die erste evidence-basierte SaaS-Plattform, die Ärzten nicht-invasiv hilft, schmerzhafte von nicht schmerzhaften Bandscheiben in der Lendenwirbelsäule zu unterscheiden. Es quantifiziert objektiv chemische Biomarker, die mit Bandscheibenschmerzen assoziiert sind, und bietet wichtige Einblicke, wenn es zusammen mit anderen Diagnosewerkzeugen verwendet wird.
Dieses Abkommen ist Teil von Aclarions Strategie, den Zugang zu Nociscan auf dem US-Markt zu erweitern, nach den jüngsten Ankündigungen zur Versicherungsdeckung im Vereinigten Königreich. Es stellt einen Schritt in Richtung potenzieller Kostenträgerdeckung in den Vereinigten Staaten dar.
- First commercial agreement in Michigan, expanding market presence
- Partnership with leading neurosurgeon Dr. John Keller, enhancing credibility
- Nociscan recognized as first evidence-supported SaaS platform for disc pain identification
- Strategic step towards potential payer coverage in the US market
- None.
Insights
Aclarion's commercial agreement with Sheridan Community Hospital marks a significant milestone in expanding access to their Nociscan technology in Michigan. This development is moderately positive for Aclarion, as it represents progress in market penetration and potential revenue growth. However, the impact is to a single hospital and region.
The collaboration with Dr. John Keller, a respected neurosurgeon, adds credibility to Nociscan's potential clinical value. This partnership could lead to further clinical validation and adoption of the technology. The focus on chronic low back pain (cLBP), a condition affecting
While this agreement is a step towards broader adoption, investors should note that widespread acceptance and insurance coverage in the US remain future goals. The company's recent success in securing UK insurance coverage is promising, but the US market may present different challenges.
This commercial agreement represents a strategic move for Aclarion in penetrating the Michigan healthcare market. While the immediate financial impact may be , it's a important step in building a presence in new regions and establishing relationships with key opinion leaders like Dr. Keller.
The chronic low back pain market is substantial, offering significant growth potential. However, Aclarion faces the challenge of competing in a crowded medical device and diagnostic space. The company's success will largely depend on its ability to demonstrate clear clinical and economic benefits over existing solutions.
Investors should monitor Aclarion's progress in securing additional commercial agreements and, more importantly, achieving insurance coverage in the US. The path from initial adoption to widespread reimbursement can be long and uncertain, which could impact the company's short to medium-term financial performance.
While this agreement is a positive development for Aclarion, its immediate financial impact is likely to be minimal. The company is still in the early stages of commercialization and revenue from a single hospital agreement is unlikely to significantly affect its financial position.
Investors should focus on Aclarion's cash burn rate and ability to secure additional funding as it expands its commercial footprint. The company's progress towards achieving positive cash flow will be crucial, given the typically long sales cycles and reimbursement challenges in the medical device industry.
The potential market size for chronic low back pain solutions is substantial, but Aclarion's ability to capture a meaningful share will depend on factors such as clinical efficacy, cost-effectiveness and successful navigation of regulatory and reimbursement landscapes. While this agreement is encouraging, it's just one step in a long journey towards commercial success and profitability.
Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan
Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor, and the Patients he Serves in Central Michigan
BROOMFIELD, CO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Sheridan Community Hospital in Sheridan, Michigan. The agreement brings Nociscan to central Michigan and leading neurosurgeon, John Keller, MD.
“As I work through how to best treat my patients, I’m excited to work with Sheridan Hospital and Nociscan to continue to develop safe, noninvasive, and cost-effective tools to help in the precise identification of disc pain,” said John Keller, MD, Neurosurgeon. “Building upon the evidence that is already mounting in favor of using MR spectroscopy and Nociscan is important work that I’m enthusiastic to undertake.”
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion’s Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain.
“At Sheridan Community Hospital, we are committed to bringing dedication and expertise to provide individual-based professional health care for the families in our community – and beyond,” says Lili Petricevic, CEO of Sheridan Community Hospital. “We are thrilled to engage with Aclarion and bring their innovative solution, Nociscan, to our community. Low back pain affects our community and Nociscan will be a valuable decision support tool when choosing treatment options.”
Aclarion has recently announced insurance coverage in the UK from leading insurers. Introducing Nociscan in markets like Sheridan continues the progression of providing access as a step on the path to payer coverage in the US.
For more information about Sheridan Hospital, please visit: https://www.sheridanhospital.com
For more information about Dr. Keller, please visit: https://greatlakesneuro.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
What is Aclarion's first commercial agreement in Michigan?
How does Nociscan help in identifying chronic low back pain?
What is the significance of Aclarion's agreement with Sheridan Community Hospital?
Who is Dr. John Keller and what is his role in this agreement?
